Zimbabwe has declined a substantial American health deal valued at $367m (£272m) spanning five years over the United States' demand for confidential information.
This move became public after a official document from December was leaked, indicating that President Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesman has since stated that the United States was demanding access to health data for research and commercial purposes but was not willing to guarantee the benefits from any future vaccines.
"We must now begin the difficult and regrettable task of winding down our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for more dialogue to find a agreement acceptable to all parties so the country's vital HIV programme can proceed.
Broader Context
This rejection comes after a comparable situation in Kenya, where a high court halted a similar deal with the US following concerns were raised about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had administered assistance for the American government, but Trump argued its spending was "wasteful" and his administration was pursuing direct bilateral deals to enhance transparency and accountability.
Based on reports, Sixteen African countries have so far agreed to similar agreements, constituting over $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation could have provided immense advantages for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment via American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information for a long time, without any equivalent promise of access to any medical innovations – such as new medicines or tests – that could result from that shared data," he stated.
"Effectively, our country would provide the raw materials for scientific discovery without any certainty that the final treatments would be accessible to our citizens if a future health crisis arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its push of bilateral deals were upending structures previously established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage future global health emergencies.
"This mechanism is intended to guarantee that when a country contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
These objections regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our US partners on how future collaboration could be arranged in a manner that honours the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body said it recognised the official position, but suggested that talks must proceed given that a large portion of the country's HIV programmes were funded by international support.
"Where technical issues exist, such as those relating to data governance or agreement terms, these can often be resolved through detailed discussion and mutually agreed protections," the group commented.
The halted deal highlights the continuing debate between receiving vital foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.